Retatrutide Triple Agonist Phase 2 Results

Informational only. Not medical advice. Retatrutide is an investigational drug not approved by the FDA for any use; it is available only through clinical trials. Gray-market "research chemical" retatrutide is illegal for human use and unverified. Do not start, stop, or change any treatment based on what you read here. Speak with a licensed clinician.

People searching "retatrutide Phase 2 results" want the actual numbers — how much weight people lost, how it compares to semaglutide and tirzepatide, and whether you can get it yet. Retatrutide (Eli Lilly's LY3437943) is the first triple-hormone-receptor agonist to reach late-stage trials, and its Phase 2 weight-loss data is the most striking in the obesity-drug field so far. Here's what the published trials actually showed. For the broader GLP-1 landscape, see our compounded GLP-1 legal and safety status guide.

What is retatrutide and how is it different from semaglutide and tirzepatide?

Retatrutide activates three receptors — GLP-1, GIP, and glucagon — while semaglutide hits one (GLP-1) and tirzepatide hits two (GLP-1 and GIP). That third target is what sets it apart. The GLP-1 component drives insulin release, glucagon suppression, slowed gastric emptying, and satiety, just like semaglutide. The GIP component adds more glucose-dependent insulin secretion and may influence fat metabolism, like tirzepatide. The novel piece is glucagon-receptor agonism: glucagon normally raises blood sugar, but in a multi-agonist it appears to increase energy expenditure and fat oxidation, adding a metabolic-rate lever the other drugs lack. The progression from single (semaglutide) to dual (tirzepatide) to triple (retatrutide) reflects a clear thesis — obesity involves several hormonal axes at once, and hitting more of them yields more weight loss.

How much weight did retatrutide cause people to lose in the Phase 2 trial?

In the Phase 2 obesity trial, the 12 mg dose produced a 24.2% mean reduction in body weight at 48 weeks, versus 2.1% on placebo — and the curve had not plateaued. The trial (Jastreboff et al., NEJM 2023) randomized 338 adults with obesity and no diabetes across four doses over 48 weeks. The results were dose-dependent and large: 1 mg gave 8.7%, 4 mg gave 17.1%, 8 mg gave 22.8%, and 12 mg gave 24.2%. Every participant on 8 mg and 12 mg lost at least 5% of body weight, and roughly 83% on 12 mg lost at least 20%. The headline that caught the field's attention: weight was still declining at week 48, suggesting the full effect wasn't yet captured. For context, semaglutide's pivotal obesity trial reached ~15% and tirzepatide's reached ~21% — retatrutide's 24.2% at a shorter 48 weeks is the highest reported for the class.

How does retatrutide work for type 2 diabetes?

In its Phase 2 diabetes trial, retatrutide cut HbA1c by up to about 2.0% and produced up to ~16.9% weight loss at 36 weeks. The trial (Rosenstock et al., Lancet 2023) enrolled 281 adults with type 2 diabetes inadequately controlled on diet or metformin. Glycemic control improved dose-dependently, with the top dose lowering HbA1c by roughly 2 percentage points — competitive with the best incretin therapies — while also driving substantial weight loss. The glucagon-receptor component theoretically raises a glucose concern, but in practice the GLP-1 and GIP insulinotropic effects dominated and glycemic control improved rather than worsened. The combination of strong A1c reduction and large weight loss is exactly the dual benefit that makes triple agonism attractive for diabetes with obesity.

What are retatrutide's side effects?

Gastrointestinal effects were the most common — nausea, diarrhea, vomiting, and constipation — dose-dependent and mostly mild to moderate. This matches the GLP-1 class pattern: GI symptoms cluster during dose escalation and ease over time. The trials also recorded a dose-dependent increase in heart rate that peaked around 24 weeks and then declined, a finding that will get close scrutiny in the larger Phase 3 program. No unexpected safety signals derailed the Phase 2 trials, but the datasets are small (a few hundred patients each) and short (36-48 weeks). The large, long Phase 3 TRIUMPH trials are designed to surface the rare adverse events that small early trials can't.

<a id="trial-table"></a>

Retatrutide Phase 2 dose-response (weight and A1c)

Metric	Placebo	1 mg	4 mg	8 mg	12 mg
Obesity trial — mean weight change, 48 wks	-2.1%	-8.7%	-17.1%	-22.8%	-24.2%
% losing ≥5% body weight (obesity)	27%	—	—	100%	100%
% losing ≥20% body weight (obesity)	low	—	—	—	~83%
Weight plateau at 48 wks?	n/a	not reached	not reached	not reached	not reached
T2D trial — HbA1c change, 36 wks	small	—	—	—	~-2.0%
T2D trial — weight change, 36 wks	small	—	—	—	~-16.9%
Most common side effect	—	GI (nausea, diarrhea) — dose-dependent, mostly mild-moderate

Obesity data: Jastreboff et al., NEJM 2023 (n=338, 48 wks). T2D data: Rosenstock et al., Lancet 2023 (n=281, 36 wks).

Where does retatrutide fit against the rest of the GLP-1 field?

The development arc is the story: semaglutide proved a single GLP-1 agonist could deliver double-digit weight loss and cardiovascular benefit; tirzepatide showed dual GIP/GLP-1 agonism pushed weight loss into the ~20% range. Semaglutide's own outcomes data keeps expanding — the SELECT and SOUL trials documented cardiovascular risk reduction and improvements in blood pressure and lipids in high-risk patients, reinforcing that this class does more than lower weight (covered in our semaglutide mechanism of action review). Retatrutide extends the thesis a third step. Its glucagon-receptor component adds an energy-expenditure pathway the others lack, which may explain why its Phase 2 weight loss exceeded both predecessors at a shorter timepoint. Whether that advantage holds across thousands of patients — and what the heart-rate signal means at scale — is what Phase 3 will decide.

Is retatrutide FDA-approved or legal to buy?

No. Retatrutide is investigational and not FDA-approved for any indication as of 2026 — it's available only through enrolled clinical trials. Eli Lilly's Phase 3 TRIUMPH program is running across obesity, diabetes, and related conditions including cardiovascular and kidney outcomes, with additional studies in MASH (fatty liver), knee osteoarthritis, and hypertension. Until those complete and the FDA reviews the data, there is no legal commercial retatrutide. Gray-market vendors selling "retatrutide" as a research compound are operating illegally for human use, and the product is unverified — purity and identity testing of gray-market GLP-1-class peptides has repeatedly found mislabeled and contaminated material. The only legitimate route to retatrutide right now is a clinical trial. For the enforcement backdrop, see our peptide legality map 2026.

Frequently asked questions

How much weight do people lose on retatrutide? In the Phase 2 obesity trial, the highest dose (12 mg) produced a 24.2% mean reduction in body weight at 48 weeks, versus 2.1% on placebo. Results were dose-dependent: 8.7% at 1 mg, 17.1% at 4 mg, and 22.8% at 8 mg. Notably, weight was still declining at week 48, so the full effect may be larger over a longer treatment period.

What is the main difference between retatrutide and semaglutide? Receptor targets. Semaglutide is a single GLP-1 receptor agonist. Retatrutide is a triple agonist hitting GLP-1, GIP, and glucagon receptors. The added GIP and glucagon activity is designed to produce greater weight loss and broader metabolic effects, and Phase 2 data showed retatrutide's weight loss exceeded semaglutide's.

Is retatrutide better than tirzepatide? In separate Phase 2 trials, retatrutide reached ~24% weight loss at 48 weeks while tirzepatide reached ~21% in its Phase 3 obesity trial at 72 weeks. The drugs haven't been compared head-to-head, so a direct claim isn't possible yet. Retatrutide's triple-receptor mechanism — adding glucagon agonism — is the theoretical reason for the larger early effect.

What are the side effects of retatrutide? The most common side effects in Phase 2 were gastrointestinal — nausea, diarrhea, vomiting, and constipation — dose-dependent and mostly mild to moderate, consistent with the GLP-1 drug class. The trials also recorded a dose-dependent heart-rate increase that peaked around 24 weeks before declining. Larger Phase 3 trials will characterize rarer risks.

Can I get retatrutide in 2026? Not through any legal commercial channel. Retatrutide is investigational and available only through enrolled Phase 3 clinical trials. It is not FDA-approved. Gray-market "research chemical" retatrutide is illegal for human use and unverified for purity or identity.

Related Reading

• Semaglutide mechanism of action: complete research review
• Compounded GLP-1 peptides: legal and safety status (2026)
• Peptide therapy vs TRT (2026)
• Peptide legality map 2026: what's legal, banned, and gray area

---

-- The Peptide Front Team